Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy of Long-Term Open-Label Dosing of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)

James B. Bussel, MD, Michael D. Tarantino, Victor S. Blanchette, Ashok Raj, Jenny Despotovic, Donald Beam, John Roy, Xuena Wang, Bhakti Mehta, Melissa Eisen

Blood (2016) 128 (22): 3738.

https://doi.org/10.1182/blood.V128.22.3738.3738

Published: 2016

Journal Articles

Cost per Treatment Success of Thrombopoietin Receptor Agonists Vs "Watch and Rescue" Strategy for Treating Adult Non-Splenectomized Patients with Chronic Immune Thrombocytopenia: A US Payer Perspective

Xiaoyan Li, PhD, Anjali Sharma, MD, Xinke Zhang, MS, Marco Campioni, PhD, Kelly Fust, MS, Junji Lin, PhD, Anju Parthan, PhD, Xuena Wang, PhD, Richard Zur, PhD, Karynsa Cetin, MPH, Melissa Eisen, MD

Blood (2015) 126 (23): 4461.

https://doi.org/10.1182/blood.V126.23.4461.4461

Published: 2015

Journal Articles

Final Results from a Phase 4 Open-Label 3-Year Study Evaluating Changes in Bone Marrow (Bm) Morphology in Adult Immune Thrombocytopenia (ITP) Patients (Pts) Receiving the Thrombopoietin Mimetic Romiplostim

Ann Janssens, Francesco Rodeghiero, David Anderson, Beng Chong, Zoltan Boda, Ingrid Pabinger, Libor Cervinek, MD PhD, Xuena Wang, Angela Lopez

Blood (2014) 124 (21): 2774.

https://doi.org/10.1182/blood.V124.21.2774.2774

Published: 2014

Journal Articles

Results From a Phase IV Open-Label Study Evaluating Changes In Bone Marrow Morphology In Adult Immune Thrombocytopenia (ITP) Patients Receiving Romiplostim: Analysis Of The 1- and 2-Year Romiplostim Cohorts

Ann Janssens, MD, Francesco Rodeghiero, David Anderson, Beng Chong, MBBS FRCPA FRACP PhD, Zoltan Boda, Ingrid Pabinger, Libor Cervinek, Xuena Wang, Angela Lopez

Blood (2013) 122 (21): 2312.

https://doi.org/10.1182/blood.V122.21.2312.2312

Published: 2013

Journal Articles

Case Studies Of Remission In Adults With Immune Thrombocytopenia (ITP) Following Cessation Of Treatment With The TPO Receptor Agonist Romiplostim

James B. Bussel, MD, Xuena Wang, Melissa Eisen, MD

Blood (2013) 122 (21): 328.

https://doi.org/10.1182/blood.V122.21.328.328

Published: 2013

Journal Articles

Integrated Analysis of Long Term Safety in Patients (pts) with Chronic Immune Thrombocytopenia (ITP) Treated with Romiplostim.

Douglas B. Cines, MD, Terry B. Gernsheimer, MD, Jeffrey Wasser, MD, Bertrand Godeau, MD, Andrew Provan, MD, Roger M. Lyons, MD, Ivy Altomare, Xuena Wang, PhD, Paul Woodard, MD

Blood (2012) 120 (21): 2185.

https://doi.org/10.1182/blood.V120.21.2185.2185

Published: 2012

Journal Articles

Use of Rituximab in a Study Comparing the Thrombopoietin Mimetic Romiplostim with Standard of Care (SOC) in Patients with Immune Thrombocytopenia (ITP),

Jeffrey Wasser, MD, Ralph Vincent V. Boccia, MD, Roger M. Lyons, MD, Romeo Mandanas, Ingrid Pabinger, Marc Michel IV, Jean-François Viallard, MD-PhD, Xuena Wang, PhD, Richard Lizambri, MD

Blood (2011) 118 (21): 3282.

https://doi.org/10.1182/blood.V118.21.3282.3282

Published: 2011

Journal Articles

Patient Quality of Life (QOL) In Nonsplenectomized Immune Thrombocytopenia (ITP) Patients Receiving Romiplostim or Medical Standard of Care (SOC)

Mathias J. Rummel, MD, PhD, David J. Kuter, MD, DPhil, Romeo Mandanas, MD, Aristoteles Giagounidis, MD, Xuena Wang, PhD, Susan D. Mathias, MPH, Robert Deuson, PhD

Blood (2010) 116 (21): 569.

https://doi.org/10.1182/blood.V116.21.569.569

Published: 2010

Journal Articles

The Effects of Romiplostim or Standard of Care (SOC) on Splenectomy and Treatment Failure of Patients Who Had Immune Thrombocytopenia (ITP) for Less Than or Equal to One Year.

Ralph Boccia, MD, David J. Kuter, MD, DPhil, Mathias J. Rummel, MD, PhD, B. Gail Macik, MD, Ingrid Pabinger, MD, Dominik Selleslag, MD, Francesco Rodeghiero, MD, Beng Chong, MBBS, PhD, Xuena Wang, PhD, Richard Lizambri, MD

Blood (2010) 116 (21): 3702.

https://doi.org/10.1182/blood.V116.21.3702.3702

Published: 2010

Journal Articles

Comparison of Splenectomy and Treatment Failure Incidence in Nonsplenectomized Patients with Immune Thrombocytopenia (ITP) Receiving Romiplostim or Medical Standard of Care: 1-Year Treatment and 6-Month Safety Follow-up.

David J Kuter, MD, DPhil, Mathias J Rummel, MD, PhD, Ralph Vincent Boccia, MD, B. Gail Macik, MD, Ingrid Pabinger, Dominik L.D. Selleslag, MD, Francesco Rodeghiero, Beng H Chong, MBBS, PhD, H. Müller-Beiβenhirtz, Lara Gehl, Xuena Wang, Dietmar Berger, MD, PhD

Blood (2009) 114 (22): 679.

https://doi.org/10.1182/blood.V114.22.679.679

Published: 2009

Journal Articles

Home Administration of Romiplostim by Patients with Chronic Immune Thrombocytopenia (ITP).

Roger M Lyons, Ralph V. Boccia, MD, Gail Macik, MD, Romeo A. Mandanas, MD, FACP, Xuena Wang, Richard Lizambri, MD, Dietmar Berger, MD, PhD

Blood (2009) 114 (22): 3510.

https://doi.org/10.1182/blood.V114.22.3510.3510

Published: 2009

NARROW

Safety and Efficacy of Long-Term Open-Label Dosing of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)

Cost per Treatment Success of Thrombopoietin Receptor Agonists Vs "Watch and Rescue" Strategy for Treating Adult Non-Splenectomized Patients with Chronic Immune Thrombocytopenia: A US Payer Perspective

Final Results from a Phase 4 Open-Label 3-Year Study Evaluating Changes in Bone Marrow (Bm) Morphology in Adult Immune Thrombocytopenia (ITP) Patients (Pts) Receiving the Thrombopoietin Mimetic Romiplostim

Results From a Phase IV Open-Label Study Evaluating Changes In Bone Marrow Morphology In Adult Immune Thrombocytopenia (ITP) Patients Receiving Romiplostim: Analysis Of The 1- and 2-Year Romiplostim Cohorts

Case Studies Of Remission In Adults With Immune Thrombocytopenia (ITP) Following Cessation Of Treatment With The TPO Receptor Agonist Romiplostim

Integrated Analysis of Long Term Safety in Patients (pts) with Chronic Immune Thrombocytopenia (ITP) Treated with Romiplostim.

Use of Rituximab in a Study Comparing the Thrombopoietin Mimetic Romiplostim with Standard of Care (SOC) in Patients with Immune Thrombocytopenia (ITP),

Patient Quality of Life (QOL) In Nonsplenectomized Immune Thrombocytopenia (ITP) Patients Receiving Romiplostim or Medical Standard of Care (SOC)

The Effects of Romiplostim or Standard of Care (SOC) on Splenectomy and Treatment Failure of Patients Who Had Immune Thrombocytopenia (ITP) for Less Than or Equal to One Year.

Comparison of Splenectomy and Treatment Failure Incidence in Nonsplenectomized Patients with Immune Thrombocytopenia (ITP) Receiving Romiplostim or Medical Standard of Care: 1-Year Treatment and 6-Month Safety Follow-up.

Home Administration of Romiplostim by Patients with Chronic Immune Thrombocytopenia (ITP).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only